NCT06998407 - Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2030

Conditions

Advanced Solid TumorHR+/HER2- Breast CancerHR+, HER2-, Advanced Breast CancerCDK Gene MutationCCND1 Gene AmplificationCDK4 Gene Amplification

Interventions

DRUG

AVZO-021

AVZO-021 is an oral selective CDK2 inhibitor

DRUG

Fulvestrant

Antineoplastic agent, estrogen receptor antagonist

DRUG

Letrozole

Antineoplastic agent, aromatase inhibitor

DRUG

AVZO-023

AVZO-023 is an oral selective CDK4 inhibitor

Trial Locations (8)

10016

NOT_YET_RECRUITING

Avenzo Therapeutics Recruiting Site, New York

22031

RECRUITING

Avenzo Therapeutics Recruiting Site, Fairfax

44106

NOT_YET_RECRUITING

Avenzo Therapeutics Recruiting Site, Cleveland

77030

NOT_YET_RECRUITING

Avenzo Therapeutics Recruiting Site, Houston

78229

RECRUITING

Avenzo Therapeutics Recruiting Site, San Antonio

90095

RECRUITING

Avenzo Therapeutics Recruiting Site, Los Angeles

06519

NOT_YET_RECRUITING

Avenzo Therapeutics Recruiting Site, New Haven

02215

NOT_YET_RECRUITING

Avenzo Therapeutics Recruiting Site, Boston